BioAtla
Dr. Mary Ann Gray has a combination of scientific and financial expertise that provides unique insights for board leadership. She has served on several public-company boards over the last 15 years including: Dyax Corp., ACADIA Pharmaceuticals, Juniper Pharmaceuticals and TetraLogic. She also currently sits on the board of Sarepta, Rapt Therapeutics, and Seneca BioPharma, Inc.. Dr. Gray has a distinguished scientific background, having completed a Ph.D. in pharmacology researching the impact of therapeutics on cardiac membranes and later focused on new drug development. Dr. Gray subsequently worked in equities research before becoming a portfolio manager.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
BioAtla
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform.